Pharmaceuticals, Biotechnology and Life Sciences
Independent Data Safety Monitoring Board (DSMB) confirms continuation of Phase II HERACLES study in acute GvHD with no safety concerns occurring within the study—
Vladislav Sandler, Chief Executive Officer of Hemogenyx Pharmaceuticals, said the potential of the ApbHC, a new generation of our humanized mice, which has allowed the company to rapidly obtain in vivo data on the efficacy of the company’s CDX antibodies against AML.
Evgen Pharma’s lead product, SFX-01, has been featured in a recently published paper, in the journal “Oxidative Medicine and Cellular Longevity”, describing Phase IIb trial in subarachnoid haemorrhage (“SAH”) at University Hospital Southampton.
EMMAC, the European independent medical cannabis company, is pleased to announce an exclusive collaboration with Hyris Ltd, a UK-based biotechnology company, to develop a comprehensive library of genetic profiles of existing cannabis varieties, and to industrialise DNA-based methods for the identification of its unique branded cultivars.
Valbiotis will participate in the first HealthTech Investor Days, being held June 24-25 in Paris.
Sanofi and Regeneron Pharmaceuticals said Friday a Phase 2 proof-of-concept trial evaluating the investigational IL-33 antibody REGN3500 (SAR440340) met the primary endpoint of improvement in loss of asthma control when comparing REGN3500 monotherapy to placebo.
Syntrix Pharmaceuticals has started its Phase 1/2 clinical trial that will combine SX-682 with KEYTRUDA, Merck’s anti-PD-1 therapy, as it dosed the first patient, it said Thursday.
Camurus will start with the Phase 3 study of once-monthly octreotide subcutaneous depot for treatment of acromegaly CAM2029.
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the initiation of a clinical trial evaluating KRYSTEXXA® (pegloticase injection) in combination with methotrexate as a strategy to increase the durability of response for patients living with chronic gout refractory to conventional therapies – also known as uncontrolled gout.
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered…